Björn Andréasson - Concepedia

Author

Björn Andréasson

Also Known As

Andreasson, Björn, B Andreasson, B Andréasson, B. ANDRÉASSON, B. Andreasson, B. Andréasson, B. I. Andreasson, Bjorn Andreasson, Björn Andreasson, Björn Andréasson

134

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

NU Hospital Group Sahlgrenska University Hospital Uddevalla sjukhus Stockholm South General Hospital University of Florence

About

Björn Andréasson is an author at NU Hospital Group specializing in medicine, hematology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	905
2	Health Sciences	3	3	198
3	Public Health	2	2	26
4	Blood Transplantation	1	1	55
5	Cell Biology	1	1	35

Björn Andréasson

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, Journal of Clinical Oncology	2012	441
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients Robyn M. Scherber, Amylou C. Dueck, Peter Johansson, Blood	2011	332
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms Magnus Björkholm, Åsa Rangert Derolf, Malin Hultcrantz, Journal of Clinical Oncology	2011	242
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis Damiano Rondelli, Judith D. Goldberg, Luis Isola, Blood	2014	149
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation Alberto Álvarez‐Larrán, Arturo Pereira, Paola Guglielmelli, Haematologica	2016	145
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients Philipp S. Goerttler, Cordula Steimle, E März, Blood	2005	97
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients Holly L. Geyer, Robyn M. Scherber, Amylou C. Dueck, Blood	2014	89
Experience with pegylated interferon -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients Krisstina Gowin, Prakash Thapaliya, John Samuelson, Haematologica ImmunologyPathologyAdvanced Myeloproliferative NeoplasmsPharmacotherapyImmunotherapy	2012	85
Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99 Peter Johansson, Jack Kutti, Björn Andréasson, Journal of Internal Medicine	2004	76

Page 1